Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)
Discontinued
Reference number: GID-TA10527
On 23 July 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for emapalumab. Following a re-examination of the opinion, at the request of the applicant, a further refusal of the marketing authorisation was given on 13 November 2020.
Therefore, the appraisal of emapalumab for treating primary haemophagocytic lymphohistiocytosis has been suspended indefinitely on the technology appraisals work programme.